Recently, the website FiercePharma has selected the top 10 Chinese biotech companies with the most attention in the world.The top ten companies are mainly focused on oncology and cardiovascular innovative drugs:

$BeiGene, Ltd. (06160.HK) $：According to FiercePharma, BeiGene, Ltd. is basically the birthplace of China's booming biotechnology industry.From R & D investment, to the first half of 2020, BeiGene, Ltd. 's R & D investment reached 4.033 billion yuan, surpassing the domestic medicine leader Hengrui Pharmaceutical.

On November 16th, BeiGene, Ltd. announced that the company plans to list on Kechuang Board, which is expected to be completed in the first half of 2021. If successfully listed in Science and Technology Innovation Board, BeiGene, Ltd. will become the first innovative pharmaceutical company to list in US, Hong Kong and A shares at the same time.

$Junshi creature (01877.HK) $：According to Fierce Pharma, Junshi's CEO, Li Ning Co. Ltd., is the only CEO on this list who has ever worked for FDA.FDA's work experience may help Junshi rush out of China and into the world.

Junshi has more than 20 pipelines under development, including VEGF, CTLA-4 and other hot targets. In addition, Junshi organism is also conducting research on neutralizing antibodies against COVID-19 virus.

$INNOVENT BIO (01801.HK) $：Fierce Pharma believes that INNOVENT BIO's PD-1 preparation Cindilizumab is definitely one of the soldiers to be reckoned with.This optimistic attitude is based on the fact that the affinity of Xindirizumab to the target is higher than that of Keytruda and Opdivo, and that Xindirizumab occupies more PD-1 binding sites than drug O.

Since Cindilizumab was included in health insurance, the company has reported sales of more than 600 million yuan in the third quarter of 2020 (an increase of more than 20% month-on-month). In addition, Cinda is a global leader in hot targets such as Shuangkang and CD47.

$I-MAB (IMAB.US) $The company has successfully built two global and Chinese product pipelines, namely, the Chinese R & D pipeline with low risk and "rapid product launch", and the global R & D pipeline with global competitiveness, high risk and "rapid proof-of-concept".

On Sept. 4, we were working on the anticancer drug, CD47 monoclonal antibody lemzoparlimab (TJC4), whose effectiveness was the best data for this target solid tumor and had no hematotoxicity.The transaction of this product not only refreshes the largest amount in the history of overseas authorized transactions by Sino Biopharmaceutical enterprises.It is also the largest authorized transaction in the global biotechnology field in the past five years.

$Zai Lab Limited (ZLAB.US) $：When introducing Zai Lab Limited, FiercePharma said its founder du Ying was known as the "godmother of the Chinese biomedical industry".Zaiding set a diversified globalization route from the very beginning, and carried out strategic cooperation with a number of leading pharmaceutical companies in the world, license-in (license introduction).

Through the introduction of new drugs being developed by international advanced pharmaceutical companies, follow-up clinical trials will be conducted in China, approved and eventually commercialized. Another Zaiding product on the market in May 2020 is the Optune, the first approved treatment for glioblastoma in China in 15 years.

$Cornerstone Pharmaceutical-B (02616.HK) $Cornerstone Pharmaceutical successfully landed in Hong Kong only three years ago. By the end of March 2020, 30 clinical trials were under way worldwide.In the industry, it has created the "myth" of "speed and quality" and attracted wide attention.

What attracted the attention of foreign investors was the $260 million round B financing in 2018, which was known as the largest round of financing for Sino Biopharmaceutical at that time.

$HUTCHMED (China) Limited (HCM.US) $：FiercePharma believes that HUTCHMED (China) Limited's further breakthrough will focus on two drugs that have reached the later stage of research and development.One is surufatinib (Sovantinib), which is the world's first phase III clinical trial of a new drug for Chinese patients with neuroendocrine tumors.

The other is MET inhibitor savolitinib (valitinib), which has achieved a breakthrough in rare mutant lung cancer in MET, and its new drug marketing application has been included in the FDA's priority review.

$Legend Biotech Corp (LEGN.US) $: data of Legend Biotech Corp's CAR-T cell therapy for recurrent refractory multiple myeloma in June 2017 (100% objective remission rate)It was called the "dark horse" of the American Society of Oncology at that time and became a blockbuster.

$and Platinum Medicine-B (02142.HK) $Although the company is still in the clinical stage,Compared with other Chinese companies on this list, Platinum Pharmaceutical is considered by FiercePharma to be the most international.He Platinum Pharmaceutical has created a leading drug discovery platform in the industry, becoming the only platform with the second generation of all-human technology in China, and has been widely used by more than 45 companies and scientific research institutions around the world, such as Pfizer Inc, Eli Lilly and Co and other global multinational pharmaceutical companies.

On May 4, scientists from Heplatinum Pharmaceutical and the University of Utrecht and Erasmus University Medical Center in the Netherlands announced that they had found that the company's drug research and development platform had effectively blocked the whole human antibody that novel coronavirus had infected cells. the drug reduces possible side effects due to immunogenicity.

$Hua Medicine-B (02552.HK) $FiercePharma said that at a time when Chinese innovative pharmaceutical companies are rushing to add new oncology drugsHua Medicine specializes in diabetes and central nervous system diseases.